A systematic review and meta‑analysis published in Cardiology Discovery shows that catheter ablation enhanced by artificial intelligence (AI) to target spatiotemporal dispersion areas yields an 87% pooled 12‑month freedom‑from‑atrial‑fibrillation rate for patients living with persistent atrial fibrillation. While early results appear encouraging, researchers emphasize that only a small number of studies exist, and larger randomized trials are required before this technique can become routine clinical care.
Persistent atrial fibrillation remains challenging to treat. Standard pulmonary vein isolation (PVI), the cornerstone of atrial fibrillation ablation, often fails to maintain long‑term sinus rhythm for persistent cases. Manual ablation targeting arrhythmogenic atrial substrate delivers highly variable outcomes because it depends heavily on individual operator experience. Artificial‑intelligence mapping tools may standardize substrate identification while preserving patient‑specific features, potentially reducing cross‑center outcome discrepancies.
Investigators performed a systematic review and meta‑analysis following PRISMA 2020 guidelines. They searched PubMed, Cochrane Library, and Europe PMC up to January 13, 2025 for studies of adults with persistent atrial fibrillation receiving pulmonary vein isolation plus artificial‑intelligence‑guided spatiotemporal dispersion area ablation. Three studies including a total of 322 patients met inclusion criteria: two observational studies and one randomized controlled trial. The primary endpoint was 12‑month freedom from atrial fibrillation assessed after the standard 3‑month post‑ablation blanking period. Bias was evaluated using the Newcastle‑Ottawa Scale for observational work and the Cochrane Risk of Bias 2 tool for the randomized trial.
Pooled analysis yielded an 87% 12‑month freedom‑from‑atrial‑fibrillation rate (95% confidence interval 82%‑91%). The single randomized controlled trial within this dataset reported 89% freedom from atrial fibrillation for the artificial‑intelligence‑guided strategy compared with 67% for pulmonary vein isolation alone (P=0.001). The procedure demonstrated acceptable safety profiles with low rates of major adverse events. Artificial‑intelligence‑supported mapping may reduce operator‑driven variability when identifying atrial arrhythmia‑causing tissue.
Important limitations temper these findings. Only three small studies qualified for synthesis; formal heterogeneity and publication‑bias assessments could not be completed. This review did not search Embase or clinical trial registries, and only English‑language articles were included. Observational data cannot prove causal benefit. Single‑procedure success metrics were inconsistently reported across source studies. Future large multicenter randomized controlled trials are needed to confirm efficacy, define optimal patient selection, and evaluate long‑term safety before artificial‑intelligence‑guided spatiotemporal dispersion ablation enters widespread clinical practice.
This article appears in Cardiology Discovery . DOI: 10.1097/CD9.0000000000000203
Cardiology Discovery
Literature review
Not applicable
Artificial Intelligence-Guided Catheter Ablation Targeting Spatiotemporal Dispersion Areas for Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis
19-Aug-2026